Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation - PubMed (original) (raw)

Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation

S Majumdar et al. J Immunol. 2001.

Abstract

Methotrexate (MTX), a folate antagonist, is a commonly used anti-inflammatory, antiproliferative, and immunosuppressive drug whose mode of action is not fully established. Due to the central role of NF-kappaB in these responses, we postulated that MTX must mediate its effects through suppression of NF-kappaB activation. We investigated the effects of MTX on NF-kappaB activation induced by TNF in Jurkat cells. The treatment of these cells with MTX suppressed TNF-induced NF-kappaB activation with optimum effects occurring at 10 microM MTX for 60 min. These effects were not restricted to Jurkat cells because other cell types were also inhibited. Besides TNF, MTX also suppressed the NF-kappaB activation induced by various other inflammatory stimuli. The suppression of TNF-induced NF-kappaB activation by MTX correlated with inhibition of IkappaBalpha degradation, suppression of IkappaBalpha phosphorylation, abrogation of IkappaBalpha kinase activation, and inhibition of NF-kappaB-dependent reporter gene expression. Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene adenosine-5'-diphosphate) blocked the effect of MTX, adenosine mimicked the effect of MTX, and adenosine A2b receptor antagonist (3,7-dimethyl-1-propargylxanthine) reversed the inhibitory effect of MTX, we suggest that MTX suppresses NF-kappaB activation by releasing adenosine. A partial reversal of MTX-induced NF-kappaB suppression by thymidine and folinic acid indicates the role of the thymidylate synthase pathway also. Overall, our results clearly demonstrate that MTX suppresses NF-kappaB activation through the release of adenosine, which may contribute to the role of MTX in anti-inflammatory, immunomodulatory, and antiproliferative effects.

PubMed Disclaimer

Cited by

NF-κB Decoy Oligodeoxynucleotide-Loaded Poly Lactic-co-glycolic Acid Nanospheres Facilitate Socket Healing in Orthodontic Tooth Movement.
Huang AC, Ishida Y, Hatano-Sato K, Oishi S, Hosomichi J, Usumi-Fujita R, Yamaguchi H, Tsujimoto H, Sasai A, Ochi A, Ono T. Huang AC, et al. Int J Mol Sci. 2024 May 10;25(10):5223. doi: 10.3390/ijms25105223. Int J Mol Sci. 2024. PMID: 38791262 Free PMC article.
Microneedles loaded with cerium-manganese oxide nanoparticles for targeting macrophages in the treatment of rheumatoid arthritis.
Xia T, Zhu Y, Li K, Hao K, Chai Y, Jiang H, Lou C, Yu J, Yang W, Wang J, Deng J, Wang Z. Xia T, et al. J Nanobiotechnology. 2024 Mar 11;22(1):103. doi: 10.1186/s12951-024-02374-y. J Nanobiotechnology. 2024. PMID: 38468261 Free PMC article.
The Expression and Activation of the NF-κB Pathway Correlate with Methotrexate Resistance and Cell Proliferation in Acute Lymphoblastic Leukemia.
Canevarolo RR, Cury NM, Yunes JA. Canevarolo RR, et al. Genes (Basel). 2023 Sep 27;14(10):1880. doi: 10.3390/genes14101880. Genes (Basel). 2023. PMID: 37895229 Free PMC article.
Ganetespib with Methotrexate Acts Synergistically to Impede NF-κB/p65 Signaling in Human Lung Cancer A549 Cells.
Subaiea G, Rizvi SMD, Yadav HKS, Al Hagbani T, Abdallah MH, Khafagy ES, Gangadharappa HV, Hussain T, Abu Lila AS. Subaiea G, et al. Pharmaceuticals (Basel). 2023 Feb 2;16(2):230. doi: 10.3390/ph16020230. Pharmaceuticals (Basel). 2023. PMID: 37259378 Free PMC article.
TAp63, a methotrexate target in CD4+ T cells, suppresses Foxp3 expression and exacerbates autoimmune arthritis.
Suga K, Suto A, Tanaka S, Sugawara Y, Kageyama T, Ishikawa J, Sanayama Y, Ikeda K, Furuta S, Kagami SI, Iwata A, Hirose K, Suzuki K, Ohara O, Nakajima H. Suga K, et al. JCI Insight. 2023 May 22;8(10):e164778. doi: 10.1172/jci.insight.164778. JCI Insight. 2023. PMID: 37212280 Free PMC article.

Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation - PubMed (original) (raw)